Video Experimental Relacionado
Updated: Sep 10, 2025
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
279
El compuesto natural estaquiosa se dirige a la reprogramación metabólica mediada por SGLT2 para mejorar la enfermedad
Resumen
La estaquiosa, un compuesto natural, se dirige al cotransportador de sodio-glucosa-2 (SGLT2) para revertir la disfunción metabólica y reducir la fibrosis renal en la enfermedad renal diabética (DKD). Esto ofrece un nuevo enfoque terapéutico para DKD.
Área de la Ciencia:
- Nefrología
- Trastornos del metabolismo
- Farmacología
Sus antecedentes:
- La enfermedad renal diabética (ERD) es una causa importante de insuficiencia renal.
- La reprogramación metabólica en las células del riñón conduce a la fibrosis en DKD.
- El cotransportador de sodio-glucosa-2 (SGLT2) agrava la disfunción metabólica en las personas con DKD.
Objetivo del estudio:
- Para encontrar un compuesto natural dirigido a SGLT2.
- Para validar su eficacia en la reversión de la reprogramación metabólica y la fibrosis renal en DKD.
Principales métodos:
- En el cribado de silicio de 4600 compuestos naturales contra SGLT2.
- Validación in vitro con células tubulares humanas y estudios in vivo en modelos de ratón con DKD.
- Evaluación de la eficacia de la estaquiosa en modelos SGLT2 con knockout y mutantes.
Principales resultados:
- La estaquiosa se une a SGLT2 en Tyr270, promoviendo la degradación y revirtiendo los cambios metabólicos.
- In vitro, la estaquiosa mejoró la oxidación de los ácidos grasos y la función mitocondrial.
- In vivo, la estaquiosa mejoró la función renal y redujo la fibrosis, efectos dependientes de SGLT2.
Conclusiones:
- La estaquiosa es un nuevo desestabilizador natural de SGLT2.
- Mejora la DKD mediante la corrección de la reprogramación metabólica en las células tubulares.
- La estaquiosa presenta una estrategia terapéutica prometedora para la DKD.
Palabras clave:
Enfermedad renal diabéticaLa reprogramación metabólicaFibrosis renalSGLT2 y SGLT2La estaquiosisMás Videos Relacionados
Videos de Conceptos Relacionados
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
256
01:27Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
01:26Glucose Absorption Into the Small Intestine
32.4K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.4K
01:32Secondary Active Transport
7.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256